Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators

被引:25
作者
Bozcuk, H
Uslu, G
Pestereli, E
Samur, M
Ozdogan, M
Karaveli, S
Sargin, F
Savas, B
机构
[1] Akdeniz Univ, Fac Med, Dept Pathol, Antalya, Turkey
[2] Akdeniz Univ, Fac Med, Dept Internal Med, Div Med Oncol, Antalya, Turkey
关键词
breast cancer; c-erbB-2; metastasis; multivariate analysis;
D O I
10.1023/A:1012269804578
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. To investigate the correlation among some of the commonly used clinical, pathological factors and newer biological indicators, and to identify the independent predictors of distant metastasis at presentation in patients with breast cancer. Methods. The pathological specimens from 73 patients with breast cancer were retrospectively evaluated by immunohistochemistry. Data on 13 biological indicators; ER, PR, P53, c-erbB-2, PCNA, CEA, Ki-67, Vimentin, Ulex, Nm23, Cathepsin D, Factor VIII, PS2 together with clinical and pathological factors were collected. Results. A number of highly significant correlations were found among the biological indicators studied. By logistic regression analysis, the predictors of distant metastasis at presentation in univariate tests were tumor diameter, number of lymph nodes involved, P53, c-erbB-2 and grade. In multivariate analysis, tumor diameter (P = 0.042, HR: 1.88(1.02-3.44)), c-erbB-2 expression (P = 0.035, HR: 18.20 (1.23-268.66)) and grade (P = 0.010, HR: 8.05(1.66-39.00)) retained their significance. Conclusion. Our findings show that inactivation of suppressor genes, expression of oncogenes, loss of differentiation, augmentation of proliferative activity, metastatic potential, angiogenesis and hormone receptor status are all interrelated facets of breast cancer pathogenesis. Patients with tumors overexpressing c-erbB-2 or with bigger or higher-grade tumors probably need to be more carefully evaluated for the presence of distant metastasis, thus be better staged, at presentation. This may be a new reason to test c-erbB-2 routinely in all patients with breast cancer in addition to its well-known prognostic and predictive uses.
引用
收藏
页码:239 / 248
页数:10
相关论文
共 26 条
[1]  
BADENOCHJONES P, 1987, INVAS METAST, V7, P284
[2]   P53 AND C-ERBB-2 PROTEIN EXPRESSION IN BREAST CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY INCLUDING CORRELATIONS WITH RECEPTOR STATUS, PROLIFERATION MARKERS, AND CLINICAL STAGE IN HUMAN BREAST-CANCER [J].
BARBARESCHI, M ;
LEONARDI, E ;
MAURI, FA ;
SERIO, G ;
PALMA, PD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (04) :408-418
[3]   ONCOGENE AMPLIFICATION AND PROGNOSIS IN BREAST-CANCER - RELATIONSHIP WITH SYSTEMIC TREATMENT [J].
BERNS, EMJJ ;
FOEKENS, JA ;
VANSTAVEREN, IL ;
VANPUTTEN, WLJ ;
DEKONING, HYWCM ;
PORTENGEN, H ;
KLIJN, JGM .
GENE, 1995, 159 (01) :11-18
[4]  
BESSE G, 1994, B CANCER, V81, P289
[5]  
COPPOLA D, 1999, JMCC, V6, P181
[6]  
Crosier M, 1999, CLIN CANCER RES, V5, P2682
[7]   P53 SWEEPS THROUGH CANCER-RESEARCH [J].
CULOTTA, E ;
KOSHLAND, DE .
SCIENCE, 1993, 262 (5142) :1958-1961
[8]   CDK-INTERACTING PROTEIN-1 DIRECTLY BINDS WITH PROLIFERATING CELL NUCLEAR ANTIGEN AND INHIBITS DNA-REPLICATION CATALYZED BY THE DNA-POLYMERASE-DELTA HOLOENZYME [J].
FLORESROZAS, H ;
KELMAN, Z ;
DEAN, FB ;
PAN, ZQ ;
HARPER, PW ;
ELLEDGE, SJ ;
ODONNELL, M ;
HURWITZ, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (18) :8655-8659
[9]  
FOEKENS JA, 1990, CANCER RES, V50, P3832
[10]  
Gillesby BE, 1999, BREAST CANCER RES TR, V56, P253